Fluorine in PDB 5lz7: Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2

Enzymatic activity of Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2

All present enzymatic activity of Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2:
3.1.1.47;

Protein crystallography data

The structure of Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2, PDB code: 5lz7 was solved by A.Woolford, P.Day, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

*Resolution Low / High (Å)*	32.99 / 2.10
*Space group*	C 1 2 1
*Cell size a, b, c (Å), α, β, γ (°)*	99.623, 91.456, 51.413, 90.00, 112.11, 90.00
*R / R_free (%)*	18 / 24.3

Other elements in 5lz7:

The structure of Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2 also contains other interesting chemical elements:

Chlorine

(Cl)

1 atom

Fluorine Binding Sites:

The binding sites of Fluorine atom in the Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2 (pdb code 5lz7). This binding sites where shown within 5.0 Angstroms radius around Fluorine atom.
In total only one binding site of Fluorine was determined in the Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2, PDB code: 5lz7:

Fluorine binding site 1 out of 1 in 5lz7

Go back to

Fluorine Binding Sites List in 5lz7

Fluorine binding site 1 out of 1 in the Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2

Mono view

Stereo pair view

A full contact list of Fluorine with other atoms in the F binding site number 1 of Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2 within 5.0Å range:

probe	atom	residue	distance (Å)	B	Occ
A:F502 b:24.3 occ:0.79	F12	A:7BK502	0.0	24.3	0.8
	C11	A:7BK502	1.4	26.2	0.8
	C10	A:7BK502	2.4	25.2	0.8
	C13	A:7BK502	2.4	23.1	0.8
	H36	A:7BK502	2.5	25.1	0.8
	C14	A:7BK502	2.8	21.5	0.8
	CD1	A:LEU159	3.2	29.5	1.0
	CD2	A:LEU107	3.3	36.0	1.0
	N15	A:7BK502	3.5	19.4	0.8
	C9	A:7BK502	3.6	24.7	0.8
	C16	A:7BK502	3.6	23.8	0.8
	O	A:HOH916	3.8	33.9	0.5
	CD2	A:PHE357	3.8	31.2	1.0
	CE2	A:PHE357	4.0	32.6	1.0
	C8	A:7BK502	4.1	24.5	0.8
	O	A:GLY154	4.1	33.7	1.0
	H35	A:7BK502	4.4	24.6	0.8
	H37	A:7BK502	4.4	23.8	0.8
	CA	A:ALA155	4.5	27.0	1.0
	CG	A:LEU159	4.6	31.2	1.0
	CG	A:LEU107	4.6	35.8	1.0
	CB	A:ALA155	4.8	26.2	1.0
	CD1	A:LEU107	4.8	35.8	1.0
	C	A:GLY154	4.8	32.1	1.0
	CG	A:PHE357	4.9	30.9	1.0
	O	A:HOH926	4.9	29.5	0.5
	N	A:ALA155	5.0	29.6	1.0

Reference:

A.J.Woolford, P.J.Day, V.Beneton, V.Berdini, J.E.Coyle, Y.Dudit, P.Grondin, P.Huet, L.Y.Lee, E.S.Manas, R.L.Mcmenamin, C.W.Murray, L.W.Page, V.K.Patel, F.Potvain, S.J.Rich, Y.Sang, D.O.Somers, L.Trottet, Z.Wan, X.Zhang. Fragment-Based Approach to the Development of An Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2). J. Med. Chem. V. 59 10738 2016.
ISSN: ISSN 1520-4804
PubMed: 27933945
DOI: 10.1021/ACS.JMEDCHEM.6B01427

Page generated: Thu Aug 1 11:37:10 2024

Last articles

Zn in 9JYW
Zn in 9IR4
Zn in 9IR3
Zn in 9GMX
Zn in 9GMW
Zn in 9JEJ
Zn in 9ERF
Zn in 9ERE
Zn in 9EGV
Zn in 9EGW

	© Copyright 2008-2020 by atomistry.com
Home \| Site Map \| Copyright \| Contact us \| Privacy